Correction: Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition

Aroa Baragaño Raneros; Alfredo Minguela; Ramon M. Rodriguez; Enrique Colado; Teresa Bernal; Eduardo Anguita; Adela Vasco Mogorron; Alberto Chaparro Gil; Jose Ramon Vidal-Castiñeira; Leonardo Márquez-Kisinousky; Paula Díaz Bulnes; Amelia Martinez Marin; Maria Carmen García Garay; Beatriz Suarez-Alvarez; Carlos Lopez-Larrea

doi:10.18632/oncotarget.26079

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition

PDF | How to cite

Oncotarget. 2018; 9:32881-32881. https://doi.org/10.18632/oncotarget.26079

Metrics: PDF 1833 views | ?

Aroa Baragaño Raneros¹, Alfredo Minguela², Ramon M. Rodriguez¹, Enrique Colado³, Teresa Bernal³, Eduardo Anguita⁴, Adela Vasco Mogorron², Alberto Chaparro Gil⁴, Jose Ramon Vidal-Castiñeira¹, Leonardo Márquez-Kisinousky¹, Paula Díaz Bulnes¹, Amelia Martinez Marin⁵, Maria Carmen García Garay⁶, Beatriz Suarez-Alvarez^1,* and Carlos Lopez-Larrea^1,*

¹ Department of Immunology, Hospital Universitario Central de Asturias, Oviedo, Spain
² Immunology Service, Instituto Murciano de Investigación Biosanitaria (IMIB), Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
³ Department of Hematology, Hospital Universitario Central de Asturias, Oviedo, Spain
⁴ Hematology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Department of Medicine, Universidad Complutense de Madrid (UCM), Madrid, Spain
⁵ Hematology Service, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
⁶ Hematology Service, Hospital General Universitario Santa Lucía, Cartagena, Murcia, Spain
^* These authors have contributed equally to this work

Published: August 28, 2018

This article has been corrected: The correct author name is given below:

Alfredo Minguela

Original article: Oncotarget. 2017; 8:31959-31976. DOI: https://doi.org/10.18632/oncotarget.16657.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26079

Publication Alerts

Corrections:

Correction: Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition